CERTIFICATE OF ANALYSIS

PuriLab Analytical

Tirzepatide 40 mg

TZ-2026-079 Lot PMBGB2 Analyzed November 20, 2026



TIMELINE

ORDERED
November 16, 2026

RECEIVED
November 19, 2026

ANALYZED
November 20, 2026

SAMPLE

NAME
Tirzepatide 40 mg

EXPECTED
Tirzepatide

AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
P.M.B Group

TEST TYPE
Content & purity

METHOD
HPLC-UV

CONTENT, HOW MUCH IS IN IT

37.01 mg

Label claim: 40 mg


PURITY, HOW CLEAN IT IS

97.8%

Measured, not estimated. Purity is calculated from the full chromatogram shown above.

CHROMATOGRAM

HPLC-UV



- 14.32 min, Tirzepatide, 97.8%

ANALYST COMMENTS

White lyophilized powder, blue-cap vial, received sealed.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: November 20, 2026

VERIFICATION CODE

TZ-I8Q7-R1EK

Verify at purilab.org/verify/TZ-I8Q7-R1EK

SCAN TO VERIFY

TZ-I8Q7-R1EK

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.